SPX3,954.68-44.16 -1.10%
DIA337.45-2.58 -0.76%
IXIC11,074.00-165.94 -1.48%

Needham Maintains Buy on Conmed, Raises Price Target to $106

Benzinga · 11/15/2022 12:29
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $90 to $106.